General Information of Drug (ID: DM8P7FC)

Drug Name
JCARH125 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1/2 [1]
Chronic lymphocytic leukaemia 2A82.0 Clinical trial [1]
Follicular lymphoma 2A80 Clinical trial [1]
Mantle cell lymphoma 2A85.5 Clinical trial [1]
Non-hodgkin lymphoma 2B33.5 Clinical trial [1]
Cross-matching ID
TTD Drug ID
DM8P7FC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Idecabtagene vicleucel DMP1QTS Multiple myeloma 2A83 Approved [2]
Belantamab mafodotin DMBT3AI Multiple myeloma 2A83 Approved [3]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [4]
Teclistamab DMGR8JI Multiple myeloma 2A83 Approved [5]
Ciltacabtagene autoleucel DMU2J7Y Multiple myeloma 2A83 Phase 3 [6]
Bb2121 DMB0UF9 Multiple myeloma 2A83 Phase 2 [7]
LCAR-B38M CAR-T Cell DMQZJNA Multiple myeloma 2A83 Phase 2 [8]
Descartes-08 DM63P1W Multiple myeloma 2A83 Phase 2 [9]
Descartes-11 DM1UO4S Multiple myeloma 2A83 Phase 2 [10]
CART-19/BCMA DMVW1GY Multiple myeloma 2A83 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell maturation protein (TNFRSF17) TTZ3P4W TNR17_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
5 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
6 ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
9 ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
10 Clinical pipeline report, company report or official report of Cartesian Therapeutics.
11 ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT